To study whether noninvasive pressure support ventilation (NIPSV) with helium/oxygen (He/oxygen), which can reduce dyspnea, PaCO 2 , and work of breathing more than NIPSV with air/oxygen in decompensated chronic obstructive pulmonary disease, could have beneficial consequences on outcome and hospitalization costs.
D uring acute decompensation of chronic obstructive pulmonary disease (COPD) (1) , increased work of breathing represents a major risk of respiratory muscle fatigue (2) (3) (4) (5) , which is often the main factor requiring intubation and mechanical ventilation (2, 6, 7) . Unloading the respiratory muscles during respiratory decompensation with noninvasive ventilation (NIV) has been shown to decrease work of breathing (8, 9) and reduce the need for intubation in COPD patients (7) , with a resultant decrease in mortality (7, 10) . There is still, however, a mean intubation rate of approximately 25% in patients undergoing NIV (7, 11) . Thus, any additional measure liable to further reduce the intubation rate would be welcome because it could lead to a reduction in the 15-30% reported mortality rate (7, 11, 12) and protracted weaning period in intubated COPD patients (13) and to a decrease in hospitalization costs (14) .
Breathing helium-oxygen (He/oxygen) instead of the standard air-oxygen (air/ oxygen) mixture reduces resistance to flow within the airways (15, 16) . Using He/oxygen during noninvasive pressure support ventilation (NIPSV) has been shown to reduce dyspnea, increase the time available for expiration, improve CO 2 elimination, and decrease work of breathing (17, 18) . Furthermore, in intubated and mechanically ventilated patients, He/oxygen can reduce intrinsic positive end-expiratory pressure and dynamic hyperinflation (19) . These data suggest that adding He/oxygen to NIPSV could help further reduce the intubation rate in acute exacerbations of COPD. The purpose of this study was to examine whether using He/oxygen during NIPSV in decompensated COPD patients could lead to a reduction in the intubation rate, intensive care unit (ICU) and hospital stays, and costs.
METHODS
Over a 24-month period, all patients with decompensated COPD, consecutively admitted to the ICUs of three university hospitals for NIV, prescribed by the physician in charge of the patient, were included in this randomized, prospective trial. Criteria for initiating NIV followed our usual practice guidelines, which are based on published studies (7, 20) and require that at least two of the following be present: worsening dyspnea during the last 10 days, respiratory rate of Ͼ25 breaths/min, arterial pH Ͻ 7.35, PaCO 2 of Ͼ50 torr, PaO 2 of Ͻ50 torr. The study was approved by the ethics committee of each institution. Informed consent was obtained from the patients. Exclusion criteria included recent pneumothorax (Ͻ1 month), severe respiratory failure or hemodynamic instability with imminent intubation, FIO 2 of Ͼ0.4, impaired consciousness or absence of patient cooperation, and facial lesions precluding NIV.
All patients were ventilated with a Veolar FT (Hamilton Medical, Rhäzuns, Switzerland) or a Servo 300 (Siemens-Elema, Solna, Sweden) (21) . Helium was administered by connecting a 50-L canister containing a 78:22 mixture of He and oxygen pressurized at 150 bar, delivered through a pressure regulator at 6 bar, directly into the ventilator's inlet normally used for air, as previously described (17, 19) .
Patients were randomized to receive NIV with either He/oxygen or air/oxygen in pressure support mode (NIPSV). Patients were blinded as to which gas mixture they were receiving. Initial level of pressure support was 15 cm H 2 O, with positive end-expiratory pressure of 5 cm H 2 O, the latter based on our clinical experience and published studies (20, 22) . Subsequent changes in these settings were based on clinical tolerance and arterial blood gases. Duration of initial NIPSV trial was set at 30 mins, as per our usual practice, to avoid patient intolerance to prolonged NIPSV on the first attempt. Additional trials were performed if any of the following were present: respiratory rate of Ͼ30 breaths/min, PaO 2 of Յ8 kPa (60 mm Hg), PaCO 2 Ն 8 kPa (60 mm Hg). The duration of additional trials was titrated according to clinical and blood gas response and patient tolerance. This discontinuous use of NIV, which has been proven beneficial by others (22) , allows better patient tolerance through a progressive increase in the duration of NIV trials and is part of our routine clinical practice guidelines for the use of NIV (23) .
In between NIPSV trials, patients in both groups breathed an air/oxygen mixture. Indeed, the purpose of the study was to compare air/oxygen and He/oxygen NIPSV based on demonstrated favorable pathophysiologic effects (17, 18) . Furthermore, continuous spontaneous breathing of He/oxygen might have added confounding variables such as time of spontaneous breathing, changes in FIO 2 , and leaks, while adding considerably to the cost and logistics aspects. The use of NIPSV in a given patient was discontinued when all the criteria for performing added trials listed above were absent for Ն18 hrs. Patients were discharged from the ICU to the ward after 24 hrs without NIPSV.
Intubation was performed in case of respiratory arrest, severe respiratory distress, impaired consciousness, agitation, cardiac rhythm or hemodynamic instability, or further worsening of blood gases despite NIPSV. Mechanical ventilation was performed with air/oxygen in both groups. Weaning from mechanical ventilation followed our standard procedure: after 48 hrs of mechanical ventilation in assist-control mode, sedation was stopped, and pressure support (level set to attain a tidal volume of Ն8 mL/kg) was initiated as soon as spontaneous breathing was present. Pressure support was then reduced decrementally to 15 cm H 2 O, and if tolerated, a 30-min T-piece trial was performed. If any signs of intolerance developed (respiratory rate of Ն35 breaths/min, arterial oxygen saturation of Ͻ90%, heart rate of Ն140 beats/ min, systolic blood pressure of Ն180 or Յ90 mm Hg, agitation, diaphoresis, anxiety), the trial was discontinued, pressure support reinstated, and a new trial performed after no more than 6 hrs on pressure support. In the absence of any of these signs, the patient was extubated.
Physiologic variables included respiratory rate, dyspnea on a visual analog scale, and blood gas evaluations performed before initiating and immediately before discontinuing the first NIPSV trial. Subsequently, these measurements were performed 4, 8, 12, 18, 24, 36, 48 , and 72 hrs after admission, while patients were off NIPSV. Outcome variables included intubation rate and duration of intensive care and hospital stays. For cost analysis, hospitalization costs for all patients were determined from the model used in the Geneva ICU. Briefly, the model, developed since 1998, is based on accounting and patient data coming from the transactional hospital information system (24), comprising admission, discharge, and transfer; encoded summaries; laboratory and radiology data; and reports, clinical findings, and images. These data are gathered, normalized, and standardized within a data warehouse called Archimed (25) . As a first step, unit costs are computed throughout analytical accounting, whereby every single Swiss franc from general accounting must be retrieved within the analytical model. Unit costs describe every aspect of the patient's hospital course (exact stay in successive wards, including operating room, laboratory or imaging exams, and nursing or physician workload). Each unit cost is computed by including both "local" costs (as salaries directly attributed to the care unit) and "imported" costs (i.e., infrastructure charges such as administration, house cleaning, and informatics). These unit costs are then distributed back to individual patients, according to their respective re-sources consumption. The final result is a precise allocation of total hospital accounting load to the patient costs. The cost of gas mixtures for each patient was determined as follows:
For each gas, the number of liters used was computed. For helium, the reading on the pressure regulator allows a determination of the number of liters left in the tank, thus allowing an estimation of total consumption. For mural outlet oxygen and compressed air: oxygen consumption (L) ϭ (average minute ventilation [L/min] ϫ duration of ventilation [mins]) ϫ FIO 2 ; and: air consumption (L) ϭ (average minute ventilation [L/min] ϫ duration of ventilation [mins]) ϫ (1-FIO 2 ).
These consumption figures were computed for each NIPSV trial, and the total consumption of gases was multiplied by their respective cost per liter to obtain the cost per patient, cost per NIPSV episode, and total costs, respectively. Reported costs for the entire study, expressed in U.S. dollars, are based on those of the Geneva hospital, extrapolated to the two other participating centers.
Statistical Analysis. Parametric methods were used in univariate and multivariate analyses of physiologic variables: Student's t-test for independent samples was used to compare groups defined by gas mixtures. Analysis of variance for repeated measurements was performed to show a global effect of gas mixture on physiologic variables, adjusting for baseline differences. Regarding the prediction of main endpoints (i.e., death and intubation), a logistic regression analysis was used after usual univariate analysis to select a small set of potential predictors. In the logistic modeling, univariate analysis consisted of Student's ttest for independent samples, in case of continuous variables, and contingency tables (Mantel-Haenszel statistic), in case of dichotomous variables. Comparison of costs between groups defined by gas mixture was performed with Wilcoxon's test, a nonparametric method, given the extremely skewed distribution of costs. Statistical significance was set at p Ͻ .05 (two-tailed values).
RESULTS
No differences in patient populations, baseline characteristics, severity of disease, clinical course, or outcome were observed between the three centers. A total of 129 patients were eligible during the 24-month period. Six patients refused inclusion. Thus, 123 patients were enrolled in the study. The male/female ratio was 71:52, age was 71 Ϯ 10 yrs, and the Acute Physiology and Chronic Health Evaluation (APACHE) II score was 17 Ϯ 4 (mean Ϯ SD). No difference in baseline characteristics of the two groups was observed (Table 1) .
Acute Response. The mean levels of pressure support at the end of the 30-min trial were 19 Ϯ 4 and 20 Ϯ 4 cm H 2 O, and those of positive end-expiratory pressure were 5 Ϯ 1.5 and 5.2 Ϯ 1.4 cm H 2 O in the air/oxygen and He/oxygen groups, respectively, these differences being nonsignificant. The response to the initial NIPSV trial is summarized in Table 2 . NIPSV improved respiratory and blood gas variables and dyspnea, and it reduced heart rate and mean arterial blood pressure, with no difference between gas mixtures being documented. Failure to improve dyspnea scale, respiratory rate, or PaCO 2 occurred respectively in 30%, 20%, and 25% of patients in the air/oxygen group and in 29%, 19%, and 23% of patients in the He/oxygen group, with all differences being nonsignificant.
Clinical Course and Outcome. The mean levels of pressure support of all subsequent NIPSV trials were 18 Ϯ 3 and 19 Ϯ 4 cm H 2 O, and those of positive end-expiratory pressure were 6 Ϯ 2 and 5 Ϯ 1.8 cm H 2 O and FIO 2 of 0.25 and 0.26 in the air/oxygen and He/oxygen groups, respectively, with these differences being nonsignificant. There was a steady improvement in dyspnea, respiratory rate, arterial pH, and PaCO 2 measured off NIPSV at the predetermined time points after admission (Fig. 1) . The difference with admission values was significant after 4 hrs already and remained significant thereafter (p Ͻ .002). However, no difference in improvement of these variables was noted between gas mixtures. Clinical course and outcome of patients are outlined in Table 3 .
A total of 21 patients required intubation (17%). There was a trend toward a lower intubation rate with He/oxygen (13.5% vs. 20.3%), although the difference was nonsignificant. No difference was noted between gas mixtures in terms of delay between ICU admission and intubation or subsequent duration of mechanical ventilation. Number and mean duration of NIPSV trials were comparable in both groups and were statistically not different between intubated and nonintubated patients. Total duration spent by all patients on NIPSV was 647 Ϯ 670 mins for air/oxygen and 545 Ϯ 461 mins for He/oxygen (mean Ϯ SD, difference not significant). Length of stay in the ICU was longer in intubated vs. nonintubated patients but was comparable in both gas mixture groups. Length of stay in the hospital after ICU was significantly shorter in the He/oxygen group, this ef-fect being limited to those patients who avoided intubation. Post-ICU hospital stay was significantly longer in intubated vs. nonintubated patients, with no difference being observed between gas mixture groups. A moderate degree of nasal skin lesions developed in eight and seven patients in the air/oxygen and He/oxygen groups, respectively. Intubation was precipitated by patient intolerance to NIPSV in seven and six patients in the air/oxygen and He/oxygen groups, respectively. Postintubation hypotension occurred in 9 of 13 and in five of eight patients in the air/oxygen and He/oxygen groups, respectively. Eight episodes of ventilatorassociated pneumonia occurred during mechanical ventilation, five in the air/ oxygen group and three in the He/oxygen group, with the difference being nonsignificant. No difference was noted between groups during the post-ICU hospital course in rate of infectious or noninfectious complications, or resting blood gases at discharge. Post-ICU care by respiratory therapists was identical in both groups, in particular, no difference being noted in the number of chest physiotherapy sessions. A total of 16 patients died (13%), 12 in the ICU and four on the ward post-ICU, with no significant difference in mortality being documented between groups. In five of the ten nonintubated patients who died (two in the air/ FEV1.0, forced expiratory volume in 1 sec, documented before admission, when patients were in steady-state; APACHE, Acute Physiology and Chronic Health Evaluation; MAP, mean arterial pressure; WBC, white blood cell count; CRP, C-reactive protein; BUN, blood urea nitrogen.
Data are presented as mean Ϯ SD; differences were not significant. Cost Analysis. During the study period, the mean cost per day per patient with COPD was $1,541.00 and $650.00 in the ICU and general ward, respectively. Because there was almost no difference in daily cost between patients who underwent NIV only and those who required endotracheal intubation and mechanical ventilation, the same figure was used to compute the cost of ICU stay. Cost of gases was $0.024/L for He/oxygen, and $0.0007/L for air/oxygen. Results of the detailed cost analysis for total and intubated and nonintubated patient subgroups for each gas mixture are shown in Table 4 . As can be seen, the cost of the gas mixture was higher in the He/oxygen group but was comparable in each group between intubated and nonintubated patients. Cost of ICU stay was similar with air/oxygen and He/oxygen and was higher in intubated vs. nonintubated patients in each group. The cost of post-ICU hospital stay was significantly lower in the He/ oxygen group, the difference being due to a lower cost in those patients in whom intubation was avoided. Likewise, total hospitalization costs, including cost of NIPSV gases, were significantly lower in the He/oxygen group because of lower costs in nonintubated patients. Finally, within each group, the cost for intubated patients was higher than those for nonintubated patients.
Post hoc Subgroup Analysis. Results from two studies on He/oxygen during NIPSV suggested a more beneficial impact of He/oxygen in cases of severe hypercapnia (17, 18) . Thus, because no benefits on intubation rate and ICU length of stay (LOS) were documented in the study, data from patients with a PaCO 2 of Ն56 torr (7.5 kPa), the level above which we had documented the most marked decrease in PaCO 2 in our previous study (17) , were analyzed as a separate group after study completion. However, no significant difference was found between gas mixture groups in any of the outcome variables studied.
DISCUSSION
To summarize, the present randomized prospective trial, the first to address outcome and cost issues during the use of He/oxygen with NIPSV, failed to show a beneficial effect of He/oxygen in terms of intubation rate and LOS in the ICU compared with air/oxygen in 123 acutely de- compensated patients with severe COPD (mean forced expiratory volume in 1 sec of Ͻ 1000 mL before decompensation). However, LOS in the hospital post-ICU was shorter for nonintubated patients who received He/oxygen, whereas cost analysis revealed that post-ICU and total hospitalization costs were lower in these patients, despite the considerably higher cost of the He/oxygen mixture. These results warrant several comments.
Acute Response to NIPSV. The rapid (30 mins) and significant improvement in respiratory rate, dyspnea, and arterial blood gases documented during the first NIPSV trial is consistent with the published series on this technique in decompensated COPD (6, 7, 11, 17, 20, 22) . In a recent trial comparing the acute effects of He/oxygen vs. air/oxygen NIPSV in 20 decompensated COPD patients, we documented a larger decrease in dyspnea and PaCO 2 with He/oxygen, the latter effect being more pronounced in patients with an initial PaCO 2 of Ͼ7.5 kPa (17). These findings were not observed in the present study. However, in the former study, ventilator settings during the NIPSV trial were protocolled, and trial duration was 45 mins (30 mins in the present study). Furthermore, the patients had been stabilized with NIPSV for Յ24 hrs before entering the former study, probably leading to improved patient-ventilator adaptation (17) .
NIPSV entailed a moderate decrease in heart rate and mean arterial pressure in both groups, probably attributable to a decrease in the adrenergic stress response stemming from respiratory dis-tress and hypercapnia. An increase in dynamic hyperinflation/intrinsic positive end-expiratory pressure due to NIPSV could also have led to a drop in mean arterial pressure, but this explanation seems less likely because this would probably have led to a rise in heart rate (26) .
Clinical Course and Outcome. One of the hypotheses of the present study was that the favorable effects of NIPSV with He/oxygen documented during shortterm pathophysiologic studies would have a beneficial impact on the clinical course and outcome of these patients. This was not the case regarding intubation rate and length of ICU stay. Several reasons could account for this. First, the intubation rate in this study was lower (all patients, 17%; air/oxygen, 20%; He/ oxygen, 13%) than the 26% rate observed in other studies (7, 11, 22) . In a recent study, a 15% intubation rate was reported in the overall population, but the rate was 36% in the more severe patients (arterial pH Ͻ 7.30) (20) . Baseline respiratory rates and arterial blood gases of our patients were comparable with those of these studies (7, 11, 20, 22) . It is quite possible that over the years the intubation rate is steadily decreasing in this patient population as more experience is gained with the use of NIPSV (27, 28) , which could explain the low rate we observed.
Regardless of the cause, the low overall intubation rate decreases the likelihood of finding a significant difference between gas mixtures, unless a very large sample population is used: in the present study, with the actual intubation rates of 13% and 20%, a power computation using commonly accepted values for alpha (type I error) of 0.05 and for 1-beta (type II error) of 0.90 would require 486 patients in each group. Thus, a type II error might explain the absence of a significant difference between the two gas mixtures. The same reasoning can apply to the absence of effect on LOS in the ICU because the short LOS in nonintubated patients (4.3 Ϯ 2.9 days with air/oxygen vs. 4.2 Ϯ 2.3 days with He/oxygen), lower than the 9 Ϯ 4 days reported by one study (22) , also renders a significant impact of the gas mixture unlikely. Finally, the heterogeneity of COPD itself should be considered. Indeed, even though the common denominator of these patients is the presence of airway obstructive disease, the predominant site or airway obstruction (i.e., proximal vs. distal airways) is not uniform among patients (29, 30) , and this can markedly influence the proportion of laminar vs. turbulent flow conditions in the airways (29, 31) . This point is important, because the beneficial influence of lowering airway resistance to flow occurs exclusively in turbulent conditions (15, 16) . Hence, the clinical impact of breathing helium is expected to vary between patients, and this could account for the lack of statistical difference between groups.
Lastly, the fact that an arterial pH Յ 7.32 at 8 hrs after admission was an independent risk factor for intubation is not surprising because in most studies on NIV, improvement is rapid (6, 7, 22) , and the absence of improvement in pH is usually associated with failure of the technique and the need for intubation (22) .
Regarding the shorter LOS in the hospital post-ICU, this difference was only significant in those patients who avoided intubation (Table 3 ). It would be tempting to explain this finding by a more H elium/oxygen did not significantly reduce the intubation rate or intensive care unit stay, but hospital stay was shorter and total costs were lower. favorable impact of NIV with He/oxygen on respiratory muscle workload and fatigue (17, 18) and thus a more rapid recovery after the acute period in the ICU in nonintubated patients, whereas this benefit would of course be lost in intubated patients. However, as there were no protocolled follow-up and discharge criteria of the post-ICU hospital stay, such a hypothesis is unverifiable. Nonetheless, improved respiratory muscle rest in COPD patients has been shown to yield prolonged beneficial effects (2, 32, 33) , which might have played a role in our patients. Pointing in that direction is the finding that, even though the duration of mechanical ventilation was not statistically different between groups, there was a clear trend toward a shorter time in the He/oxygen group (Table 3) , which also could have stemmed from a shorter weaning time due to less respiratory muscle fatigue. These hypotheses should be explored further in the future.
One final point that emerges from this study is that He/oxygen can be used safely with NIPSV in COPD, provided that some of the pitfalls regarding ventilator function are known (21) , as underlined by the absence of complications directly attributable to its use.
Hospitalization Costs. Analyzing total costs associated with hospitalization is a difficult task because most studies lack the complete data on the various aspects discussed above (34 -36) and therefore cannot report the true daily cost of hospital stay in a fully integrated manner (28) . Access to such data in our institution allowed such an approach and provides a fairly exact picture of this financial aspect. Naturally, extrapolation of these data to the two other participating centers, mandated by the fact that the database is available only in Geneva, implies that absolute figures are not correct, as costs vary between institutions and countries. Nonetheless, relative differences between groups and subgroups remain valid in this context.
As expected, the cost of gases was considerably higher in the He/oxygen group. However, the cost of gas mixtures represented a very small fraction (Ͻ1%) of total costs, as can be seen from Table 4 . Hence, this added cost was largely offset by the savings stemming from the shorter hospital LOS in nonintubated patients. In this subgroup, mean savings per patient was $3,291 for post-ICU stay and $3,348 for total hospitalization. Interestingly, this figure approaches the cost savings of $3,244 per patient admission attributable to NIV compared with standard therapy in COPD patients reported in a recent study using metaanalysis and cost modeling (14) .
Weaknesses of Study. Several weaknesses of our study should be addressed. First, even though patients were blinded to the gas mixture they were receiving, the investigators were not. This option was chosen because of the considerable technical difficulties inherent to blinding in such a setting. Indeed, canisters of compressed air should have been used and markings of all canisters removed, which would increase logistic difficulties and costs. Furthermore, true blinding is unlikely to be achieved because the sound made by ventilator valves when helium is used has a different pitch, easily recognized by staff members accustomed to working with helium, the same being true for the patient's voice pitch. One last important issue is that, in pressure support mode with helium, the ventilator reports a lower tidal volume than actually delivered (21) , which could lead to unnecessary and potentially deleterious increases in the level of pressure support if the clinician is not aware of this artifact. Second, NIPSV was not strictly protocolled, nor were mechanical ventilation and weaning in intubated patients. However, strict protocol of such procedures, besides being technically very difficult to implement, implies that gas mixtures are compared in conditions not reflecting everyday clinical practice, which are those very conditions in which cost-effectiveness information is needed. Furthermore, all three institutions followed the practice guidelines summarized in the methods section, so bias in approach was less likely, as further confirmed by the absence of significant difference in NIPSV or conventional mechanical ventilation times between air/oxygen and He/oxygen groups. Third, even though ICU discharge followed practice guidelines, no such guidelines were present regarding hospital discharge. However, after ICU stay, patients were under the care of totally different medical and nursing staffs and respiratory therapists, who were unaware of the study, making bias unlikely. Fourth, one of the reasons why the cost of He/oxygen represented only a small fraction of total ICU costs might stem from our policy of intermittent rather than continuous use of NIPSV, the mean duration of trials in the He/oxygen group being 102 Ϯ 228 mins. We have found this approach to allow better patientventilator adaptation and patient tolerance to the technique, as have others (22) . Naturally, prolonged daily use of NIPSV, as sometimes reported (37, 38) would be expected to increase gas mixture costs and reduce savings. However, considering only nonintubated patients, and assuming the same mean minute ventilation and FIO 2 , and identical ICU and post-ICU LOS, tripling mean daily duration of NIPSV from 2.5 to 7.5 hrs/day would crank up the mean cost of gases per patient from $1.61 to $4.83 and from $68 to $204 in the air/oxygen and He/ oxygen groups, respectively. In turn, this would increase the ICU and total hospitalization costs compared with Table 4 , but there would still be no difference between groups regarding the former (air/oxygen, $6,651, vs. He/oxygen, $6,460), whereas the significant difference in the latter would remain present (air/oxygen, $18,229, vs. He/oxygen, $15,080; p Ͻ .05).
In conclusion, although the present study failed to show a significant reduction in the intubation rate or shortening of ICU stay in COPD patients receiving NIPSV with He/oxygen instead of air/ oxygen, it did demonstrate a shorter duration of post-ICU hospitalization in patients in whom intubation was avoided. Consequently, a significant reduction in total hospitalization costs was documented in these patients. Further studies should aim at identifying subgroups of patients most likely to benefit from the use of He/oxygen during NIPSV, as it could prove to be a safe and cost-effective approach in the treatment strategy of decompensated COPD. Pending the results of such trials, however, we consider the present study as insufficient evidence to recommend the routine use of He/oxygen NIPSV in this situation.
